<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01226108</url>
  </required_header>
  <id_info>
    <org_study_id>Aktin study</org_study_id>
    <nct_id>NCT01226108</nct_id>
  </id_info>
  <brief_title>The Akloma Tinnitus Patch in Patients With Manifested Tinnitus</brief_title>
  <acronym>Aktin</acronym>
  <official_title>The Akloma Tinnitus Patch in Patients With Manifested Tinnitus (the Aktin Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akloma Bioscience AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akloma Bioscience AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      Primary Objective The primary objective will be a decrease of inconvenience with at least 10%
      for at least 50% of the subjects.

      Secondary Objectives

      The secondary objective will be to:

      To evaluate if the patch can improve the tinnitus patient's quality of life and sleep
      quality.

      METHODOLOGY

      Study Design:

      An open safety and performance clinical investigation of the antinitus patch in patients with
      manifested tinnitus.

      Treatment Duration:

      1 patch per day for 3 weeks

      Primary Endpoint:

      Tinnitus severity questionnaire (TSQ)

      Performance Parameters:

      Tinnitus severity questionnaire (TSQ) and numerical rating scale (NRS) measuring tinnitus
      annoyance.

      Quality of life and sleep quality

      Safety Parameters: Adverse Reactions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>7 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tinnitus severity questionnaire score as a measure of efficacy</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Tinnitus</condition>
  <arm_group>
    <arm_group_label>antinitus patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One patch per day, Duration: three weeks, Administration: behind the ear</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Patch</intervention_name>
    <description>One patch per day, Duration: three weeks, Administration: behind the ear</description>
    <arm_group_label>antinitus patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of both sexes &gt; 18 years of age

          -  Signed informed consent

          -  Patients who have suffered from tinnitus for ≥ 4 weeks before study entry

          -  Manifested tinnitus grade II or above on the Klockhoff-Lindblom tinnitus severity
             grading scale.

          -  Tinnitus score of 5 or above (numerical rating scale for tinnitus annoyance)

          -  Pure tone averages better than 40 dB in the worse hearing ear.

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Malignancy or other serious medical conditions

          -  Skin disease

          -  Simultaneous or previous (within 30 days prior to study entry) participation in a
             clinical study using experimental drugs or devices.

          -  Severe psychiatric disorder

          -  Serious suicidal risk

          -  Patients who have started treatment or made changes in treatment with drugs known to
             influence tinnitus within 6 weeks before study start.

          -  Patients with untreated high blood pressure ≥140/90 mmHg

          -  Other tinnitus treatment within 6 weeks before study entry.

          -  Previous use of the Antinitus patch

          -  Known allergy or sensitivity to any of the compounds in the Antinitus or the placebo
             patches.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Åhnblad</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sickla ÖNH-center / Supramed AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sickla ÖNH-center, Atlashuset Planiavägen 5</name>
      <address>
        <city>Nacka</city>
        <zip>131 34</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2010</study_first_submitted>
  <study_first_submitted_qc>October 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2010</study_first_posted>
  <last_update_submitted>September 23, 2011</last_update_submitted>
  <last_update_submitted_qc>September 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

